Soligenix prices public offering of common stock and warrants for $7.4M.

Soligenix, a late-stage biopharmaceutical company, has priced a public offering of 5,555,560 shares of common stock and warrants to purchase up to 5,555,560 shares of common stock at a combined purchase price of $1.35 per share. The warrants will have an exercise price of $1.35 per share and expire five years from the issuance date. The offering is expected to generate proceeds for the company.

Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company, has priced its public offering of 5,555,560 shares of common stock and warrants to purchase up to 5,555,560 shares of common stock at a combined purchase price of $1.35 per share. The offering is expected to generate approximately $7.5 million in gross proceeds before deducting placement agent fees and other estimated expenses.

The warrants, with an exercise price of $1.35 per share, will be exercisable immediately and expire five years from the issuance date. The company has also agreed to amend certain existing warrants to have a reduced exercise price of $1.35 per share and an expiration date commensurate with the warrants sold in the offering.

The closing of the offering is expected to occur on or about September 29, 2025, subject to customary closing conditions. Soligenix intends to use the net proceeds from this offering to fund research and development, commercialization activities, working capital, and general corporate purposes.

Alliance Global Partners is acting as the sole placement agent in connection with the offering. The securities are being offered pursuant to a registration statement on Form S-1 (File No. 333-290413), which became effective on September 25, 2025. A preliminary prospectus relating to the offering has been filed with the Securities and Exchange Commission (SEC).

Soligenix is focused on developing and commercializing products to treat rare diseases with unmet medical needs. The company's Specialized BioTherapeutics business segment is developing HyBryte™ (SGX301) as a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). The Public Health Solutions business segment includes development programs for RiVax®, a ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses and CiVax™ for COVID-19 prevention.